 |
ARCHIVE # 4: 554 ARTICLES (NOV -SEPT 2006) |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||||
| Click here to read messages from our MySpace Friends HERE'S A FEW OF OUR 1,404 MySpace FRIENDS |
||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||||
| July 2013 | ||||||||||||||||||||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||||||||||||||||||||
Tuesday, September 26, 2006
Fampridine-SR Data Sends Acorda Stock Through Roof: Shares in Acorda Therapeutics Inc. rocketed by more than 282 percent Monday on positive findings from a Phase III study of Fampridine-SR in multiple sclerosis. [MORE]:
"........34.8 percent of people taking Fampridine-SR had improved walking speed, compared to 8.3 percent for those on placebo as measured by the Timed 25-Foot Walk, the study's primary outcome (p<0.001).>
'If you are a timed-walk responder,' Cohen explained, 'you also are statistically likely to say, blindly, that your walking is better at home. Your activities of daily life are better, and you've improved, clinically.'
The average increase in walking speed over the treatment period compared to baseline was 25.2 percent among Fampridine-SR vs. 4.7 percent for the placebo group. Increased response rate on the Timed 25-Foot Walk was seen across all four major types of MS: primary-progressive, secondary-progressive, relapsing-remitting and progressive-relapsing. In addition, statistically significant increases in leg strength were seen in both the Fampridine-SR timed-walk responders (p<0.001) p="0.046)">
'It is possible to get discreet improvements,' Cohen said, 'depending on where your lesions are, as an individual, and what the drug is able to restore...."
"........34.8 percent of people taking Fampridine-SR had improved walking speed, compared to 8.3 percent for those on placebo as measured by the Timed 25-Foot Walk, the study's primary outcome (p<0.001).>
'If you are a timed-walk responder,' Cohen explained, 'you also are statistically likely to say, blindly, that your walking is better at home. Your activities of daily life are better, and you've improved, clinically.'
The average increase in walking speed over the treatment period compared to baseline was 25.2 percent among Fampridine-SR vs. 4.7 percent for the placebo group. Increased response rate on the Timed 25-Foot Walk was seen across all four major types of MS: primary-progressive, secondary-progressive, relapsing-remitting and progressive-relapsing. In addition, statistically significant increases in leg strength were seen in both the Fampridine-SR timed-walk responders (p<0.001) p="0.046)">
'It is possible to get discreet improvements,' Cohen said, 'depending on where your lesions are, as an individual, and what the drug is able to restore...."